Camillo Porta

Research interests

Publications

• Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

  Annals of Oncology · 2024 · https://doi.org/10.1016/j.annonc.2024.05.537

• Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

  Cancer · 2022 · 10.1002/cncr.34180

• Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial

  The Lancet Oncology · 2022 · 10.1016/s1470-2045(22)00290-x

• Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2035716

• Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival

  JAMA Network Open · 2021 · https://doi.org/10.1001/jamanetworkopen.2020.21869

• Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

  New England Journal of Medicine · 2021 · 10.1056/nejmoa2026982

• Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

  ESMO Open · 2020 · 10.1136/esmoopen-2020-001079

• Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2019 · 10.1093/annonc/mdz056

• Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

  The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(19)30723-8

• Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(19)30413-9

• Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

  New England Journal of Medicine · 2018 · 10.1056/nejmoa1712126

• Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

  The Lancet Oncology · 2018 · https://doi.org/10.1016/s1470-2045(18)30146-3

• Choosing the right cell line for renal cell cancer research

  Molecular Cancer · 2016 · 10.1186/s12943-016-0565-8

• Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2016 · 10.1093/annonc/mdw328

• Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study

  Journal of Clinical Oncology · 2014 · https://doi.org/10.1200/jco.2013.50.8267

• Targeting PI3K/Akt/mTOR Signaling in Cancer

  Frontiers in Oncology · 2014 · 10.3389/fonc.2014.00064

• Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2014 · 10.1093/annonc/mdu259

• Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

  The Lancet Oncology · 2012 · https://doi.org/10.1016/s1470-2045(12)70490-4

• Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2012 · 10.1093/annonc/mds227

• Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial

  Journal of Hepatology · 2012 · 10.1016/j.jhep.2012.06.014

• Phase 3 trial of everolimus for metastatic renal cell carcinoma

  Cancer · 2010 · https://doi.org/10.1002/cncr.25219

• Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

  The Lancet Oncology · 2009 · https://doi.org/10.1016/s1470-2045(09)70162-7

• Sorafenib in Advanced Hepatocellular Carcinoma

  New England Journal of Medicine · 2008 · 10.1056/nejmoa0708857

• Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

  The Lancet · 2008 · https://doi.org/10.1016/s0140-6736(08)61039-9

• Phase III Randomized Controlled Trial Comparing the Survival of Patients With Unresectable Hepatocellular Carcinoma Treated With Nolatrexed or Doxorubicin

  Journal of Clinical Oncology · 2007 · 10.1200/jco.2006.08.4046

Current projects

No projects listed.